---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-115300"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-10-13T12:35:19+00:00"
generated_at: "2026-10-13T12:40:15.165677+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# MetaVia names Sarah Browne, M.D. Chief Medical Officer; DA-1726 Phase 1 Part 3 data due Q4 2026

## Summary
- Sarah Browne, M.D. appointed Chief Medical Officer effective October 12, 2026, with more than 20 years in clinical development, regulatory science and clinical medicine.
- Browne was VP of Clinical Development at Altimmune, leading pemvidutide (dual GLP-1/glucagon receptor agonist) from first-in-human through Phase 2 and an FDA End-of-Phase 2 meeting.
- Earlier she was Senior Advisor for Clinical Review at the FDA's CBER and an assistant clinical investigator at NIH; she has authored 40+ peer-reviewed publications.
- CEO Hyung Heon Kim said she joins as MetaVia prepares for anticipated Q4 2026 topline data from Part 3 of the Phase 1 trial of DA-1726 at 48 mg and 64 mg doses.
- Company is also developing vanoglipel (DA-1241) for the treatment of MASH, alongside its DA-1726 cardiometabolic program.

## SEC filing metadata
- accession: 0001104659-26-115300
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-10-13T12:35:19+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926115300/0001104659-26-115300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926115300/mtva-20261013x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-115300
- JSON: https://secwatch.observer/filing/0001104659-26-115300.json
- Plain text: https://secwatch.observer/filing/0001104659-26-115300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.